| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical used in a therapeutic method applicable for systemic treatment, as a new treatment strategy for treating a cancer systemically, reducible of a dose of an applied cancer therapeutic medicine, and/or capable of increasing an efficiency. <P>SOLUTION: The present invention relates to use of at least one kind of integrin ligand for preparing the pharmaceutical of cancer therapy by isolated organ perfusion, cyclo-(Arg-Gly-Asp-DPhe-NMe-Val) is contained as the integrin ligand, the pharmaceutical is used in paprallel with a cancer combination therapeutic medicine, the cancer combination therapeutic medicine is selected from the group comprising melphalan, a cyclophosphamide, doxorubicin, cisplatin, carboplatin, gemcitabine, docetaxel, paclitaxel, bleomycin, 5FU and TNFα, and an isolated organ is selected from the group comprising a liver, a lung, a kidney, a pleura, and a pancreas, in the use. <P>COPYRIGHT: (C)2013,JPO&INPIT |
